Trials / Withdrawn
WithdrawnNCT06598631
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate the efficacy and safety of Volenrelaxin in adults with Chronic Kidney Disease. The study will last about 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Volenrelaxin | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2024-10-09
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2024-09-19
- Last updated
- 2025-10-02
Locations
35 sites across 5 countries: United States, Australia, China, Japan, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06598631. Inclusion in this directory is not an endorsement.